Novo Nordisk A/S (NVO)
| Market Cap | 214.27B |
| Revenue (ttm) | 49.58B |
| Net Income (ttm) | 16.30B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.67 |
| PE Ratio | 13.06 |
| Forward PE | 13.53 |
| Dividend | $1.23 (2.57%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 15,290,251 |
| Open | 48.94 |
| Previous Close | 47.99 |
| Day's Range | 47.83 - 49.12 |
| 52-Week Range | 43.08 - 112.52 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 54.25 (+13.35%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $54.25, which is an increase of 13.35% from the latest price.
News
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?
Novo Nordisk's semaglutide failed in pivotal studies as a treatment for Alzheimer's disease. This isn't a significant obstacle to the drugmaker's prospects, despite what the market reaction suggests.
India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact
Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and lifestyle coaching, after signing a deal with Novo Nordisk's India unit, its...
Wegovy's prices are going down, but they are ‘wildly different' — and confusing
It depends on a patient's medical coverage, of course, but also on an increasingly tangled web of federal policies and corporate pricing strategies, along with the ability to do good old-fashioned res...
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment
Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on Wedne...
Novo Nordisk gears up for December Ozempic launch in India, sources say
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold in the world's ...
Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock?
The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped following this news, signaling that it's not as bad as it seems at first g...
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials
Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday,...
Here's Why Novo Nordisk Just Paid $2.1 Billion For Zaltenibart
Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now ...
Novo Nordisk to test next-gen obesity drug CagriSema in children
Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry of clinical trials.
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.
Semaglutide failed to demonstrate slowed Alzheimer's progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ~4...
Why Novo Nordisk Stock Just Hit a 4-Year Low
Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.
Novo Nordisk: Headwinds On The Surface, Deep Value If You Dig
Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of 1...
Novo Nordisk: A Textbook Value Trap
Novo Nordisk A/S (NVO), though cheap at 13x forward earnings, is in my view a value trap, as growth is slowing and GLP-1 pricing pressures are capping revenue and profitability. The TrumpRx platform w...
Novo Nordisk Stock Investors Get Huge News on Drug Trial Results
The company revealed critical information that investors will not want to miss.
How Medicare's new drug prices could reshape Novo Nordisk and european pharma
Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk's blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts...
Why Novo Nordisk Stock Is Moving Higher Today
Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The application is under expedited FDA review, with a decision expected within one to two...
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy
On Wednesday, Novo Nordisk A/S (NYSE: NVO) submitted its supplemental marketing application to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg for chronic...
Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies
The IRA from 2022 allows the CMS to negotiate prices for a number of drugs each year for patients in Medicare. Late Tuesday, the agency announced newly negotiated prices for 15 blockbuster drugs from ...
Novo Nordisk Seeks FDA Approval of Higher Dose of Wegovy Weight-Loss Shot
The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.
Novo shares rise as US Medicare price cuts come in largely as expected
Novo Nordisk shares rose 5% on Wednesday after analysts said that U.S. price cuts for the Danish drugmaker's semaglutide came in broadly as expected.
Wall Street Breakfast Podcast: HP Downsizes To Power Up
HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on O...
Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter
Novo Nordisk A/S (NYSE: NVO) shouldn't be trading like a meme stock — not when it's sitting on deep-value fundamentals, a GLP-1 fortress, and a pipeline pivot that could flip 2026 from bruised to brea...
Here's Why Novo Nordisk Stock Popped Today
The company's highly promising drug, amycretin, reported impressive results in a trial for Type 2 diabetes. The news follows on for a disappointing, but hardly unexpected, result in a Phase 3 trial fo...
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says
Novo Nordisk A/S (NYSE: NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer's ...
Novo Nordisk: Forget About Alzheimer's, The Real Catalyst Is The Wegovy Pill
Novo Nordisk A/S remains the market leader in obesity and diabetes treatments, despite a recent sharp stock drop and failed Alzheimer's trial. The real growth catalyst for NVO is the upcoming oral sem...